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PROPHYLACTIC SCLEROTHERAPY: YES OR NO!
ABSTRACT
Koch, H., Binmoeller, K.F., Grimm, H., Soehendra, N., Henning, H. and Oehler, G.
(1994) Prophylactic sclerotherapy for esophageal varices: Long-term results
ofa prospective study. Endoscopy; 26: 729-733.
Controlled trials of endoscopic sclerotherapy for the prevention of the first variceal
hemorrhage have given controversial results. We continued a previously reported study
and randomly assigned 141 patients with esophageal varics and no prior gastrointestinal
bleeding to either prophylactic sclerotherapy (n 70) or no treatment (n 71). Sclero-
therapy was performed until complete eradication of the varices was achieved; recurrent
varics were treated with repeat sclerotherapy. The groups were well balanced in terms of
demographic and clinical characteristics. Patients in both groups who bled from varices
received sclerotherapy whenever possible.
During a median follow-up of 56 months, variceal bleeding occurred in 7% in
sclerotherapy patients and 44% on control patients (p < 0.01). In the sclerotherapy
group 59% died, and in the control group 51% (n.s.). In both groups, the mortality rate
increased with the severity of liver function impairment. Sclerotherapy was not found to
improve survival in patients, irrespective of the etiology of cirrhosis (alcoholic or
nonalcoholic) or variceal size (low-grade or high-grade).We conclude that sclerotherapy
is a suitable method to reduce the occurrence ofthe first variceal hemorrhage, but it does
not appear to have an effect on survival.
Paquet, K-J., Kalk, J-F, Klein, C-P. and Gad, H.A. (1994) Prophylactic sclerotherapy
for esophageal varices in high-risk cirrhotic patients selected by endoscopic and hemo-
dynamic criteria: A randomised, single-center controlled trial Endoscopy; 26: 734-740.
Controlled trials of sclerotherapy for the prevention of the first variceal hemorrhage in
cirrhotics have given conflicting results, in spite of an initial positive controlled trial. We
designed therefore a new study in which only 89 of 396 investigated patients were
randomized to sclerotherapy (44 patients) or a control group (45 patients). The admis-
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sion criteria were: no history of variceal bleeding, the presence of high risk varices, i.e,
varcies ofdegrees III and IV with minivarices on the surface ofthem, and portal pressure
over 16mmHg. Sclerotherapy sessions were performed at 0, 7, 14, 21, and 28 days, untill
the varices were reduced in size and completely covered by fibrous tissue. Follow-up
endoscopy was performed at four-month and thereafter at six-month intervals. The
control patients underwent repeated clinical investigation and endoscopy at six-month
intervals. Bleeding episodes were treated by emergency endoscopic sclerotherapy in both
groups, whenever possible. The mean follow-up was 33 months. The results were
analyzed using Student’s t-test and the log-rank test. Variceal bleeding occured in 11
sclerotherapy patients (25%) and 34 controls (75.6%) (p < 0.05). The overall mortality
was 25% (11 patients) among the sclerotherapy patients and 69% (31 patients) in the
controls (p < 0.01). Prophylactic endoscopic sclerotherapy was able to prolong survival
in Child-Pugh classesA and B, but not in C. It is concluded that prophylactic endoscopic
sclerotherapy does reduce the incidence of first variceal bleeding in cirrhotic patients,
and is able to prolong survival if only high-risk patients are selected and the treatment is
performed by endoscopic experts.
KEYWORDS: Scleotherapy Prophylactic sclerotherapy oesophageal varices.
PAPER DISCUSSION
The benefits ofprophylactic sclerotherapy in cirrhotics
who have not bled from varices are controversial. As
beta blockers have been shown to have benefit (1) with
clinical and statistical homogeneity as regards efficacy,
beta blockers are the current standard and accepted
therapy. A meta-analysis of beta blocker therapy,
propranolol or nadolol, reduced the incidence ofbleed-
ing at a statistically significant level and increase sur-
vival albeit, this just misses statistical significance (1).
The results of sclerotherapy have been very varied,
meta-analysis showing heterogeneity i.e. a wider vari-
ation than that expected by chance considering each
trial as a repeated experiment (1). The reasons for
heterogeneity might lie in different operators e.g. the
American studies report a higher frequency of
serious side-effects and have increased mortality (2)
or in different populations-alcoholics may respond
differently (3). However, the most obvious reason
lies in the different baseline bleeding risks of the
populations which entered these studies, from 20% to
70%. The high baseline risk of bleeding, either means
there has been selection of patients, but this is not
apparent from the studies, or mis-selection perhaps
including patientswho had hadminor bleeds. Interest-
ingly there is a relationship between greater efficacy of
sclerotherapy and lower quality score for each trial
when reasons for heterogeneity were examined (1).
It is now known that large varices, red signs and
worse liver function predict a higher bleeding risk (4),
so that selection of patients might be possible. Lastly,
it should be remembered that sclerotherapy does
not prevent bleeding from portal hypertensive gastro-
pathy, and this is a source of first gastrointestinal
bleeding in cirrhotics.
Against this background one can evaluate the re-
suits of 2 recently published prophylactic sclero-
therapy trials. One by Koch et al. is a longer follow up
report with more patients of a previously published
study (5), and the second is a new trial by Paquet et al.
the authors of the first prophylactic study (6) who
repeated a prophylactic study with selection of
cirrhotics at high risk of first bleeding.
The trial by Koch et al. describes 2 separate trials.
There was an initial recruitment period which repre-
sented the first study published (5), then a gap of 3
years before further recruitment. The latter is in effect
a separate study and the results should have been
presented as separate. Unfortunately, the datawas not
presented for the second period ofrecruitment.A total
of 140 patients were recruited. There was no selection
for size of varices. Polidocanol 1% was injected intra
and para variceal. The follow up was less intensive in
the control group every 12 months, compared to the
close initial followup because ofthe variceal injections
in the sclerotherapy group, and, therefore, 3-6
monthly. The mean follow up was 56 months (26 to
140 months). There were 13 of 70 patients bleeding in
the sclerotherapy group compared to 31 of 70 in the
control group (p < 0.001) and death due to bleeding
was 6 in the injected group and 17 in the control group.
Surprisingly no patient is documented as bleeding
from portal hypertensive gastropathy-perhaps this
did occur but was not evaluated. Despite this there was
no difference in mortality by Kaplan-Meier plots. In
fact there were more deaths in the sclerotherapy
group, 41, than the control group 36. As death due toHPB INTERNATIONAL 187
bleeding was 50% in the control group and 85% in the
injected group one would have expected a difference in
survival. Serious complications of sclerotherapy were
low in the second period, only patient, compared to 6
in the first phase.
This trial shows no survival benefit for prophylactic
sclerotherapy. The benefit in prevention of bleeding
was not evaluated in terms of length of hospital stay,
endoscopy workload nad patient acceptability. Given
that the phased recruitment may have influenced re-
sults, and that beta blockers are cheaper and simpler to
administer, this trial does not change current practice
for prophylaxis of variceal bleeding nor suggest fur-
ther studies of sclerotherapy.
The trial by Paquet et al. is far more interesting. In
this study a deliberate attempt was made to recruit
patients at high risk ofbleeding. Thus, those with large
varices and "varices on varices" (red signs)(4) together
with those with a hepatic venous pressure gradient of
> 16mmHg were selected. From a consecutive series of
396 patients only 89 fulfilled the criteria. Patients in the
control group were followed up 6 monthly so that
there was an attempt to make the frequency ofvisits in
the 2 groups similar. Polidocanol 0.5% to 1% was
injected para and intravariceally. In this study there
was a marked difference in the occurrence of upper
gastrointestinal bleeding: 13 of44 in the sclerotherapy
group but 35 of 45 in the control group (p < 0.05).
Portal hypertensive gastropathy bleeding was re-
ported in 3. Survival was also improved in the
sclerotherapy group 11 v 31 deaths (p < 0.01). When
analysed by Child’s groups, this was only true for
groupsA and B, as there was no difference in Child’sC
patients. In this trial there is the expected improvement
in survival, secondary to the reduction in bleeding.
There were 3 major complications in the sclerotherapy
group (including ulcer bleed included in the bleeding
group above). The authors appear to have selected out
a population with at least a 70% bleeding risk, the
highest in the literature. Based on the North Italian
Endoscopic Club criteria of a bleeding risk of at least
40%, another prophylactic sclerotherapy study (7)
could not show benefit in survival, although there was
a difference in bleeding.
Whether the addition of the haemodynamic par-
ameter of hepatic venous pressure gradient allowed
Paquet et al. to more accurately select a group at high
risk of bleeding from varices remains to be proven by
further study. It is feasible that this cut off is clinically
significant, as for similar size varices a greater pressure
will increase tension on the wall to a greater degree and
cause rupture of the varix.
New prophylactic trials for prevention of first
variceal bleeding should target subgroups ofcirrhotics
at greater risk of bleeding. Portal pressure should be
measured ab initio and beta blocker therapy should be
the control arm. The study by Paquet et al. has re-
opened the question ofprophylactic endoscopic treat-
ment for varices but again does not indicate that a
change in current clinical practice is needed. Beta
blockers remain the treatment of choice.
Whether banding ligation should replace sclero-
therapy, also needs to be evaluated. The complication
rate in these 2 trials is lower than previously reported
with sclerotherapy. Overtube complications with
banding are potentially serious, so that it may not be
an automatic choice for endoscopic treatment
prophylactically. In any case banding ligation should
only be compared to beta-blockers. Ideally measure-
ment ofportal pressure should be undertaken, to con-
firm Paquet’s results.
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